Trial Profile
Sorafenib Administered Using a High-dose, Pulsatile Regimen in Patients With Advanced Solid Malignancies: a Phase I Exposure Escalation Study
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Apr 2022
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Acronyms SOPRANO
- 18 Oct 2018 Status changed from recruiting to completed.
- 05 Jun 2018 Results (n=17) presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 06 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.